Angela Cheung

Dr. Angela Cheung


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2023 in Hepatology Communications
Verified
Journal Article
Open access
CBChristopher L. Bowlus
Christopher L. Bowlus
BEBertus Eksteen
Bertus Eksteen
ACAngela Cheung
Angela Cheung
DTDouglas Thorburn
Douglas Thorburn
CMCynthia A. Moylan
Cynthia A. Moylan
CLCynthia Levy
Cynthia Levy
Background: Primary sclerosing cholangitis (PSC) is frequently associated with pruritus, which significantly impairs quality of life. Maralixibat is a selective ileal bile acid transporter (IBAT) inhibitor that lowers circulating bile acid (BA) levels and reduces pruritus in cholestatic liver diseases. This is the first proof-of-concept study of IBAT inhibition in PSC. Methods: This open-label study evaluated the safety and tolerability of maralixibat ≤10 mg/d for 14 weeks in adults with PSC. Measures of pruritus, biomarkers of BA synthesis, cholestasis, and liver function were also assessed. Results: Of 27 enrolled participants, 85.2% completed treatment. Gastrointestinal treatment-emergent adverse events (TEAEs) occurred in 81.5%, with diarrhea in 51.9%. TEAEs were mostly mild or moderate (63.0%); 1 serious TEAE (cholangitis) was considered treatment related. Mean serum BA (sBA) levels decreased by 16.7% (−14.84 µmol/L; 95% CI, −27.25 to −2.43; p = 0.0043) by week 14/early termination (ET). In participants with baseline sBA levels above normal (n = 18), mean sBA decreased by 40.0% (−22.3 µmol/L, 95% CI, −40.38 to −4.3; p = 0.004) by week 14/ET. Liver enzyme elevations were not significant; however, increases of unknown clinical significance in conjugated bilirubin levels were observed. ItchRO weekly sum scores decreased from baseline to week 14/ET by 8.4% (p = 0.0495), by 12.6% (p = 0.0275) in 18 participants with pruritus at baseline, and by 70% (p = 0.0078) in 8 participants with ItchRO daily average score ≥3 at baseline. Conclusions: Maralixibat was associated with reduced sBA levels in adults with PSC. In participants with more severe baseline pruritus, pruritus improved significantly from baseline. TEAEs were mostly gastrointestinal related. These results support further investigation of IBAT inhibitors for adults with PSC-associated pruritus. ClinicalTrials.gov: NCT02061540.

4 March 2020 in European Radiology
Verified
Journal Article
Closed access
PDF file
MTMonica Tafur
Monica Tafur
ACAngela Cheung
Angela Cheung
RMRavi J. Menezes
Ravi J. Menezes
JFJordan J Feld
Jordan J Feld
HJHarry Janssen
Harry Janssen
KJKartik S. Jhaveri
Kartik S. Jhaveri

26 July 2018 in European Radiology
Verified
Journal Article
Closed access
PDF file
KJKartik S. Jhaveri
Kartik S. Jhaveri
HHHooman Hosseini-Nik
Hooman Hosseini-Nik
NSNima Sadoughi
Nima Sadoughi
HJHarry Janssen
Harry Janssen
JFJordan J Feld
Jordan J Feld
ACAngela Cheung
Angela Cheung

1 November 2021 in Canadian Liver Journal
Verified
Journal Article
Open access
Aldo J. Montano-LozaAldo J. Montano-Loza
Aldo J. Montano-Loza
JAJessica R Allegretti
Jessica R Allegretti
ACAngela Cheung
Angela Cheung
MEMaryam Ebadi
Maryam Ebadi
DJDavid Jones
David Jones
GHGideon Hirschfield
Gideon Hirschfield
Autoimmune liver disease (AILD) spans a spectrum of chronic disorders affecting the liver parenchyma and biliary system. Three main categories of AILD are autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). This review condenses the presentation and discussions of the Single Topic Conference (STC) on AILD that was held in Ottawa, Ontario, in November 2019. We cover generalities regarding disease presentation and clinical diagnosis; mechanistic themes; treatment paradigms; clinical trials, including approaches and challenges to new therapies; and looking beyond traditional disease boundaries. Although these diseases are considered autoimmune, the etiology and role of environmental triggers are poorly understood. AILDs are progressive and chronic conditions that affect survival and quality of life. Advances have been made in PBC treatment because second-line treatments are now available (obeticholic acid, bezafibrate); however, a significant proportion still present suboptimal response. AIH treatment has remained unchanged for several decades, and data suggest that fewer than 50% of patients achieve a complete response and as many as 80% develop treatment-related side effects. B-cell depletion therapy to treat AIH is in an early stage of development and has shown promising results. An effective treatment for PSC is urgently needed. Liver transplant remains the best option for patients who develop decompensated cirrhosis or hepatocellular carcinoma within specific criteria, but recurrent AILD might occur. Continued efforts are warranted to develop networks for AILD aimed at assessing geo-epidemiological, clinical, and biochemical differences to capture the new treatment era in Canada.

1 October 2018 in Gastroenterology
Verified
Journal Article
Open access
PDF file
KLKonstantinos N. Lazaridis
Konstantinos N. Lazaridis
ACAngela Cheung
Angela Cheung

20 July 2023 in Journal of Hepatology
Verified
Journal Article
Closed access
HSHussain Syed
Hussain Syed
GVGreg Vallée
Greg Vallée
BABishoi Aziz
Bishoi Aziz
NSNing Sun
Ning Sun
MOMohamed Osman
Mohamed Osman
AMAndrew Mason
Andrew Mason